Auris Medical Holding AG (NASDAQ:EARS) released its quarterly earnings results on Thursday. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. During the same quarter in the prior year, the company earned ($0.15) EPS.

Auris Medical Holding AG (NASDAQ:EARS) opened at 1.04 on Friday. The stock has a 50 day moving average of $1.35 and a 200 day moving average of $2.84. The firm’s market cap is $35.70 million. Auris Medical Holding AG has a 52 week low of $0.84 and a 52 week high of $7.96.

Earnings History for Auris Medical Holding AG (NASDAQ:EARS)

Large investors have recently made changes to their positions in the stock. TFS Capital LLC raised its stake in shares of Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock valued at $160,000 after buying an additional 5,762 shares during the period. Advisor Group Inc. acquired a new stake in shares of Auris Medical Holding AG during the second quarter valued at about $277,000. Finally, Bellevue Group AG acquired a new stake in shares of Auris Medical Holding AG during the first quarter valued at about $7,897,000. 31.01% of the stock is currently owned by hedge funds and other institutional investors.

EARS has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Auris Medical Holding AG from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Needham & Company LLC boosted their price target on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, August 19th. Finally, JMP Securities downgraded shares of Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 18th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $8.88.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

5 Day Chart for NASDAQ:EARS

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.